Filing Details
- Accession Number:
- 0000899243-16-025639
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-07-25 16:05:24
- Reporting Period:
- 2016-07-21
- Filing Date:
- 2016-07-25
- Accepted Time:
- 2016-07-25 16:05:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1512762 | Coherus Biosciences Inc. | CHRS | Biological Products, (No Disgnostic Substances) (2836) | 273615821 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1622139 | K. Peter Watler | C/O Coherus Biosciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City CA 94065 | Chief Technical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2016-07-21 | 3,991 | $2.08 | 3,991 | No | 4 | M | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2016-07-21 | 3,291 | $26.05 | 700 | No | 4 | S | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2016-07-21 | 700 | $26.48 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2016-07-21 | 3,991 | $0.00 | 3,991 | $2.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 88,503 | 2022-12-13 | No | 4 | M | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $25.41 to $26.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from $26.42 to $26.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- All shares underlying this option are vested and exercisable as of the date hereof.
Billionaire Hedge Funds
